Pegah Nammian1, Seyedeh-Leili Asadi-Yousefabad2, Sajad Daneshi3, Mohammad Hasan Sheikhha4,5, Seyed Mohammad Bagher Tabei6,7, Vahid Razban8,9. 1. Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Department of Molecular Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 3. Postdoctoral Researcher, Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Biotechnology Research Center, International Campus, Shahid Sadoughi University of MedicalSciences, Yazd, Iran. 5. Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 6. Department of Genetics, Shiraz University of Medical Science, Shiraz, Iran. mtabei63@gmail.com. 7. Maternal-fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. mtabei63@gmail.com. 8. Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. razban_vahid@yahoo.com. 9. Stem Cells Technology Research center, Shiraz University of Medical Sciences, Shiraz, Iran. razban_vahid@yahoo.com.
Abstract
INTRODUCTION: Critical limb ischemia (CLI) is the most advanced form of peripheral arterial disease (PAD) characterized by ischemic rest pain and non-healing ulcers. Currently, the standard therapy for CLI is the surgical reconstruction and endovascular therapy or limb amputation for patients with no treatment options. Neovasculogenesis induced by mesenchymal stem cells (MSCs) therapy is a promising approach to improve CLI. Owing to their angiogenic and immunomodulatory potential, MSCs are perfect candidates for the treatment of CLI. The purpose of this study was to determine and compare the in vitro and in vivo effects of allogeneic bone marrow mesenchymal stem cells (BM-MSCs) and adipose tissue mesenchymal stem cells (AT-MSCs) on CLI treatment. METHODS: For the first step, BM-MSCs and AT-MSCs were isolated and characterized for the characteristic MSC phenotypes. Then, femoral artery ligation and total excision of the femoral artery were performed on C57BL/6 mice to create a CLI model. The cells were evaluated for their in vitro and in vivo biological characteristics for CLI cell therapy. In order to determine these characteristics, the following tests were performed: morphology, flow cytometry, differentiation to osteocyte and adipocyte, wound healing assay, and behavioral tests including Tarlov, Ischemia, Modified ischemia, Function and the grade of limb necrosis scores, donor cell survival assay, and histological analysis. RESULTS: Our cellular and functional tests indicated that during 28 days after cell transplantation, BM-MSCs had a great effect on endothelial cell migration, muscle restructure, functional improvements, and neovascularization in ischemic tissues compared with AT-MSCs and control groups. CONCLUSIONS: Allogeneic BM-MSC transplantation resulted in a more effective recovery from critical limb ischemia compared to AT-MSCs transplantation. In fact, BM-MSC transplantation could be considered as a promising therapy for diseases with insufficient angiogenesis including hindlimb ischemia.
INTRODUCTION:Critical limb ischemia (CLI) is the most advanced form of peripheral arterial disease (PAD) characterized by ischemic rest pain and non-healing ulcers. Currently, the standard therapy for CLI is the surgical reconstruction and endovascular therapy or limb amputation for patients with no treatment options. Neovasculogenesis induced by mesenchymal stem cells (MSCs) therapy is a promising approach to improve CLI. Owing to their angiogenic and immunomodulatory potential, MSCs are perfect candidates for the treatment of CLI. The purpose of this study was to determine and compare the in vitro and in vivo effects of allogeneic bone marrow mesenchymal stem cells (BM-MSCs) and adipose tissue mesenchymal stem cells (AT-MSCs) on CLI treatment. METHODS: For the first step, BM-MSCs and AT-MSCs were isolated and characterized for the characteristic MSC phenotypes. Then, femoral artery ligation and total excision of the femoral artery were performed on C57BL/6 mice to create a CLI model. The cells were evaluated for their in vitro and in vivo biological characteristics for CLI cell therapy. In order to determine these characteristics, the following tests were performed: morphology, flow cytometry, differentiation to osteocyte and adipocyte, wound healing assay, and behavioral tests including Tarlov, Ischemia, Modified ischemia, Function and the grade of limb necrosis scores, donor cell survival assay, and histological analysis. RESULTS: Our cellular and functional tests indicated that during 28 days after cell transplantation, BM-MSCs had a great effect on endothelial cell migration, muscle restructure, functional improvements, and neovascularization in ischemic tissues compared with AT-MSCs and control groups. CONCLUSIONS: Allogeneic BM-MSC transplantation resulted in a more effective recovery from critical limb ischemia compared to AT-MSCs transplantation. In fact, BM-MSC transplantation could be considered as a promising therapy for diseases with insufficient angiogenesis including hindlimb ischemia.
Authors: Guo-Cai Li; Hong-Wei Zhang; Qing-Chun Zhao; L I Sun; Jian-Jun Yang; Liu Hong; Fan Feng; Lei Cai Journal: Oncol Lett Date: 2015-12-03 Impact factor: 2.967
Authors: Thom W Rooke; Alan T Hirsch; Sanjay Misra; Anton N Sidawy; Joshua A Beckman; Laura Findeiss; Jafar Golzarian; Heather L Gornik; Michael R Jaff; Gregory L Moneta; Jeffrey W Olin; James C Stanley; Christopher J White; John V White; R Eugene Zierler Journal: J Am Coll Cardiol Date: 2013-03-06 Impact factor: 24.094
Authors: Tormod S Westvik; Tamara N Fitzgerald; Akihito Muto; Stephen P Maloney; Jose M Pimiento; Tiffany T Fancher; Dania Magri; Hilde H Westvik; Toshiya Nishibe; Omaida C Velazquez; Alan Dardik Journal: J Vasc Surg Date: 2008-11-22 Impact factor: 4.268
Authors: Leila Haghighat; Sophia Elissa Altin; Robert R Attaran; Carlos Mena-Hurtado; Christopher J Regan Journal: J Clin Med Date: 2018-04-14 Impact factor: 4.241
Authors: Marta Rojas-Torres; Ismael Sánchez-Gomar; Antonio Rosal-Vela; Lucía Beltrán-Camacho; Sara Eslava-Alcón; José Ángel Alonso-Piñeiro; Javier Martín-Ramírez; Rafael Moreno-Luna; Mª Carmen Durán-Ruiz Journal: Stem Cell Res Ther Date: 2022-06-21 Impact factor: 8.079